ArticleEuropean archives of psychiatry and clinical neuroscience2017
Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study.
Article in European archives of psychiatry and clinical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.BMC psychiatry · 2024Pooled it
- Pooled it
- Molecular basis underlying changes of brain entropy and functional connectivity in major depressive disorders after electroconvulsive therapy.CNS neuroscience & therapeutics · 2024Article
- Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms.BMC medicine · 2024Article
- Genetic variation of the 5-HT1A rs6295, 5-HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients.Brain and behavior · 2023Article
- Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review.International journal of molecular sciences · 2022Review
- Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia.Molecular neurobiology · 2022Review
- Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.International journal of molecular sciences · 2022Review
- Commonalities for comorbidity: Overlapping features of the endocannabinoid system in depression and epilepsy.Frontiers in psychiatry · 2022Review
- Association of Innate and Acquired Aerobic Capacity With Resilience in Healthy Adults: Protocol for a Randomized Controlled Trial of an 8-Week Web-Based Physical Exercise Intervention.JMIR research protocols · 2021Article
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Differential effect of interferon-alpha treatment on AEA and 2-AG levels.Brain, behavior, and immunity · 2020Article
- The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid.European archives of psychiatry and clinical neuroscience · 2020Article
- Cannabinoids and their therapeutic applications in mental disorders .Dialogues in clinical neuroscience · 2020Review
- Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Endocannabinoid System Components as Potential Biomarkers in Psychiatry.Frontiers in psychiatry · 2020Review
- Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders.Frontiers in behavioral neuroscience · 2020Article
- Article
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
- Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.Neuromolecular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the lack of clinical data about the role of the endocannabinoid system (ECS) in affective disorders, preclinical work suggests that the ECS is relevant in both with regard to the etiology of depression as well as the mediation of antidepressant effects. We measured the intraindividual levels of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid of 12 patients suffering from a major depressive episode before and after the antidepressant treatment by electroconvulsive therapy (ECT). AEA was significantly elevated after ECT as compared to baseline. The AEA increase positively correlated with the number of individually performed ECT sessions. Although the sample size was small and confounders were not rigorously controlled for, our finding corroborates preclinical work and should encourage further exploration of the involvement of the ECS in depressive disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.